#1 Clinical Trials Search in Europe

Vibosameran

This article explores the use of Vibosameran, a novel drug being studied in clinical trials for the treatment of advanced melanoma. Vibosameran is one of the active substances in BNT111, a combination therapy being tested in patients with late-stage skin cancer that has not responded to other forms of treatment. The trial aims to evaluate the effectiveness and safety of BNT111 alone and in combination with another drug called cemiplimab in patients with unresectable Stage III or IV melanoma.

Table of Contents

What is VIBOSAMERAN?

VIBOSAMERAN is an innovative medication being studied for the treatment of advanced melanoma, a serious form of skin cancer[1]. It is part of a group of substances called BNT111, which includes other components such as gindameran, enomimeran, and ontasameran. These substances work together to potentially fight melanoma cells.

VIBOSAMERAN is also known by other names, including RBL002 and RBL002.4. It’s important to note that this medication is still in the research phase and is not yet approved for general use[1].

How Does VIBOSAMERAN Work?

VIBOSAMERAN is a type of treatment called mRNA therapy. mRNA stands for messenger RNA, which is a molecule that carries instructions for making proteins in our cells. In this case, VIBOSAMERAN contains mRNA that instructs cells to produce a protein called tyrosinase[1].

Tyrosinase is a protein often found in melanoma cells. By causing the body to produce this protein, VIBOSAMERAN aims to “train” the immune system to recognize and attack melanoma cells that contain tyrosinase. This approach is a form of immunotherapy, which uses the body’s own immune system to fight cancer[1].

Who is VIBOSAMERAN For?

VIBOSAMERAN is being studied for patients with advanced melanoma, specifically those with:

  • Stage III or IV (metastatic) cutaneous melanoma that cannot be surgically removed
  • Cancer that has not responded to or has come back after treatment with anti-PD-1 or anti-PD-L1 therapies (other types of immunotherapy)
  • Measurable disease according to specific criteria (RECIST 1.1)

Patients must have received at least one but no more than five previous treatments for their advanced melanoma[1].

Current Clinical Trial

VIBOSAMERAN is currently being studied in a Phase II clinical trial. This trial is:

  • Open-label: meaning both patients and doctors know which treatment is being given
  • Randomized: patients are randomly assigned to different treatment groups
  • Comparing BNT111 (which includes VIBOSAMERAN) alone, in combination with another drug called cemiplimab, and cemiplimab alone

The main goal of this trial is to see how well BNT111 and cemiplimab work together in shrinking tumors[1].

Potential Benefits

While it’s important to remember that VIBOSAMERAN is still being studied, researchers hope it may:

  • Shrink tumors or slow their growth
  • Improve overall survival for patients with advanced melanoma
  • Provide a new treatment option for patients whose cancer has not responded to other therapies

The clinical trial will measure things like how many patients’ tumors shrink, how long the treatment effects last, and how long patients live after starting treatment[1].

Possible Side Effects

As with any medical treatment, VIBOSAMERAN may cause side effects. The current clinical trial is carefully monitoring for:

  • Any adverse events that occur during treatment
  • Serious or life-threatening side effects
  • Immune-related adverse events (side effects related to the immune system)
  • Changes in laboratory test results or vital signs

The researchers are also tracking patients’ quality of life during treatment to understand how the medication affects overall well-being[1].

How is VIBOSAMERAN Administered?

VIBOSAMERAN is given as an intravenous injection, which means it’s injected directly into a vein. The maximum daily dose being studied is 100 micrograms, with a total maximum dose of 3750 micrograms over the course of treatment[1].

The treatment period can last up to 104 weeks (about 2 years), but this may vary depending on how patients respond to the treatment[1].

Aspect Details
Trial Type Phase II, open-label, randomized
Main Drug BNT111 (containing Vibosameran)
Combination Drug Cemiplimab
Target Condition Unresectable Stage III or IV melanoma
Patient Criteria Adults with disease progression after anti-PD-1/PD-L1 therapy
Primary Endpoint Objective Response Rate (ORR)
Secondary Endpoints Duration of response, disease control rate, overall survival, safety profile
Administration Intravenous injection
Follow-up Period Up to 104 weeks

FAQ

  • What is Vibosameran? Vibosameran is one of the active substances in BNT111, a new drug being tested for advanced melanoma treatment. It is a type of mRNA that encodes for tyrosinase, a protein involved in melanin production.
  • Who is eligible for this clinical trial? The trial is for adults (18 years or older) with unresectable Stage III or IV melanoma who have not responded to previous anti-PD-1/PD-L1 treatments. Patients must have confirmed disease progression and meet specific health criteria.
  • What is the main goal of this clinical trial? The main goal is to demonstrate the anti-tumor activity of BNT111 in combination with cemiplimab, measured by the objective response rate (ORR) according to specific criteria called RECIST 1.1.
  • How is the drug administered in this trial? BNT111, which contains Vibosameran, is administered through intravenous injection. The exact dosing schedule and amounts are determined by the trial protocol.
  • What are the potential benefits and risks of participating in this trial? Potential benefits include access to a new treatment for advanced melanoma. Risks may include side effects from the treatment, which are being closely monitored. The trial also assesses the safety profile and impact on quality of life for patients receiving the treatment.

Ongoing Clinical Trials on Vibosameran

  • Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Poland Spain

Glossary

  • Melanoma: A type of skin cancer that develops in cells called melanocytes, which produce the pigment that gives skin its color.
  • Unresectable: Unable to be removed completely through surgery, often due to the location or spread of the cancer.
  • Stage III melanoma: Cancer has spread to nearby lymph nodes but not to distant parts of the body.
  • Stage IV melanoma: Cancer has spread to distant parts of the body, such as the lungs, liver, brain, or other areas of the skin.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Anti-PD-1/PD-L1 therapy: A type of immunotherapy that helps the immune system recognize and attack cancer cells.
  • Cemiplimab: An immunotherapy drug used in combination with BNT111 in this trial.
  • mRNA: Messenger RNA, a molecule that carries genetic information used to make proteins in the body.
  • Tyrosinase: An enzyme involved in the production of melanin, the pigment that gives color to skin, hair, and eyes.

References

  1. http://clinicaltrials.eu/trial/study-of-bnt111-and-cemiplimab-for-patients-with-advanced-melanoma-unresponsive-to-prior-treatments/